Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2016 - 2026)

Akebia Therapeutics has reported Other Non-Current Liabilities over the past 11 years, most recently at $1.8 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 64.78% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 64.78% year-over-year, with the annual reading at $1.8 million for FY2025, 64.78% down from the prior year.
  • Other Non-Current Liabilities was $1.8 million for Q4 2025 at Akebia Therapeutics, down from $5.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $85.4 million in Q2 2021 and troughed at $760000.0 in Q4 2022.
  • The 5-year median for Other Non-Current Liabilities is $6.8 million (2024), against an average of $27.6 million.
  • Year-over-year, Other Non-Current Liabilities surged 4416.56% in 2021 and then crashed 99.09% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.8 million in 2021, then crashed by 58.24% to $760000.0 in 2022, then changed by 0.0% to $760000.0 in 2023, then surged by 581.05% to $5.2 million in 2024, then plummeted by 64.78% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Non-Current Liabilities are $1.8 million (Q4 2025), $5.0 million (Q3 2025), and $14.2 million (Q2 2025).